Pepvise
Compound profile· Compounds

Thymosin alpha-1, what the evidence shows

By The PepVise Editorial Team · Reviewed July 2, 2026 · 14 min read

Evidence Ledger for thymosin alpha-1 (Talpha1): an immune-modulating thymic peptide approved in several countries as Zadaxin for hepatitis B and C and as a vaccine enhancer, but not FDA-approved in the US. What the studies show, and what they do not.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature

PubMed saved search, 'thymosin alpha 1'

Thymosin alpha-1 is unusual for this category because it has a genuine clinical literature and approvals outside the US. A saved search shows the exact scope: solid immunology and hepatitis trials in specific countries, but no FDA approval and no support for the broad anti-aging and longevity claims it is marketed with online. The search separates the approved from the promoted more honestly than any summary.

Reference reading

The texts we read alongside the papers.

  1. 01
    Primary literature

    PubMed saved search, 'thymosin alpha 1'

    A PubMed search surfaces the defining distinction: a substantial body of work on immunomodulation and on use in hepatitis B and C and as a vaccine adjuvant, alongside a near-total absence of rigorous data supporting the broad anti-aging and longevity promises. It is the fastest way to separate what has actually been studied from what is being sold.

  2. 02
    Reference text

    Williams Textbook of Endocrinology (14th ed.)

    Thymosin alpha-1 is a thymic peptide that influences T-cell maturation and function, standard immunology. Williams and standard immunology references supply the cell and receptor biology needed to read the mechanistic claims critically, without the performance-marketing layer that vendor and forum pages add. Read it for the physiology, not for use guidance.

  3. 03
    Popular-science background

    Outlive, Peter Attia, MD (with Bill Gifford)

    Attia's distinction between an approved indication backed by endpoint data and an extrapolated longevity claim is exactly the discipline thymosin alpha-1 requires, because its strongest data sit in hepatitis and vaccine immunology, not in aging. It does not cover the peptide directly; the reasoning framework is the point.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is thymosin alpha-1 FDA-approved?
Not in the US. Thymosin alpha-1 (trade name Zadaxin) is approved in several countries for chronic hepatitis B and C and as a vaccine enhancer, but it has no FDA approval in the United States. There it circulates off-label or as a compounded or research product labeled for non-human use.
What is thymosin alpha-1 actually used for?
The solid data concern immunomodulation: as an adjunct in chronic hepatitis B and C and as an adjuvant that strengthens the vaccine response, in the countries where it is approved. It has also been studied in sepsis and, during the pandemic, in severe COVID-19, with mixed and non-definitive results. The anti-aging and longevity marketing goes far beyond these approved uses.
Is thymosin alpha-1 the same as thymosin beta-4 or TB-500?
No. They are distinct peptides that happen to share the thymosin naming. Thymosin alpha-1 is an immune-modulating peptide with hepatitis and vaccine data and approvals abroad. Thymosin beta-4, and its fragment marketed as TB-500, is a different actin-binding peptide framed around tissue repair, with a much thinner human evidence base.
Does thymosin alpha-1 slow aging or boost longevity?
There is no evidence that it does. Its documented effects are immunological and sit in specific infectious and immune contexts. The anti-aging and longevity claims are extrapolation from that immunology, not outcomes any trial has demonstrated, and should be treated as marketing rather than fact.
Why does PepVise not give a thymosin alpha-1 dose?
Because we describe the literature and do not recommend administration. Even where thymosin alpha-1 is approved, dosing belongs with a treating physician; the figures repeated online for off-label use come from forums. We explain how these substances are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.